Navigation Links
ViroPharma to Present at Two May Healthcare Conferences
Date:5/7/2009

EXTON, Pa., May 7 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Bank of America/Merrill Lynch 2009 Healthcare Conference at 8:00 A.M. ET on Wednesday, May 13, 2009. The conference is being held at the Palace Hotel in New York City.

ViroPharma also announced that Charles Rowland, vice president and chief financial officer of ViroPharma will present at the Deutsche Bank 2009 Healthcare Conference at NOON ET on Monday, May 18, 2009. The conference is being held at the InterContinental Hotel in Boston.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... THR ... “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified CBD product utilizes Quicksilver ... the bloodstream. Far outpacing the absorption speed of all other products, ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... a contract to Quality Insights to help small practices in Delaware, New Jersey, ... Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). ...
(Date:2/22/2017)... Cranbury, NJ (PRWEB) , ... February 22, 2017 ... ... full-service healthcare communications company, launched a new media platform connecting healthcare technology professionals ... which will be followed by a quarterly publication starting on March 1, announced ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. ... dogs, according to the Association for Pet Obesity Prevention (APOP). During the ninth annual ... issues such as the benefits of corn and grains, value of raw and organic ...
(Date:2/22/2017)... Dallas, TX (PRWEB) , ... February 22, 2017 ... ... of security threats. Yet with so many different solutions on the market, it ... through their choices, Texas Premier Locksmith offers a complimentary security consultation. ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... -- According to a new market research report "Gynecology ... (Laparoscopy, Colposcopy, Hysteroscopy, D&C, Ablation, Biopsy), & End User (Hospital, Clinic, ... the global market is expected to reach USD 2.44 Billion by ... 7.1% during the forecast period. Continue ... ...
(Date:2/22/2017)... 22, 2017 Arthroscopy Devices Market Report, published by Allied Market ... is projected to reach $5,334 million by 2022, growing at a CAGR of 6.2% ... market in 2015. Continue Reading ... ...      ...
(Date:2/22/2017)... Research and Markets has announced the ... 2016" report to their offering. ... Dermatological conditions are one ... one-third of the US population suffers from at least one ... the dermatology market has remained saturated with established and generic ...
Breaking Medicine Technology: